Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)547.36
  • Today's Change-0.38 / -0.07%
  • Shares traded51.00
  • 1 Year change-46.55%
  • Beta0.3249
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

  • Revenue in USD (TTM)14.09bn
  • Net income in USD4.50bn
  • Incorporated1988
  • Employees15.11k
  • Location
    Regeneron Pharmaceuticals Inc777 Old Saw Mill River RoadTARRYTOWN 10591United StatesUSA
  • Phone+1 (781) 370-5000
  • Websitehttps://www.regeneron.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
REGN:NSQ since
announced
Transaction
value
23andMe Holding CoAnnounced19 May 202519 May 2025Announced-7.90%256.00m
Oxular LtdDeal completed31 Dec 202431 Dec 2024Deal completed-22.09%--
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ICON PLC8.19bn758.19m11.93bn41.25k16.331.269.991.469.199.1999.32119.560.4852--3.01195,528.004.493.705.394.4629.0829.009.257.41--5.820.2647--1.9924.1729.2616.1827.11--
Exelixis Inc2.30bn643.57m12.59bn1.15k20.945.9618.695.472.202.207.887.750.81513.238.802,004,291.0022.829.5126.4410.7796.7896.3227.9915.613.44--0.000.0018.4917.51150.8910.1817.25--
Summit Therapeutics Inc0.00-240.76m18.23bn159.00--52.88-----0.3309-0.33090.000.46430.00----0.00-85.89-78.31-95.86-86.84-------31,307.77----0.00------64.01---16.43--
Insmed Inc381.03m-1.01bn18.55bn1.27k--179.41--48.69-5.95-5.952.210.54510.25730.97538.98299,787.60-68.42-44.83-88.04-51.7976.4977.08-265.93-226.785.44-31.800.9194--19.1721.66-21.91---12.30--
Iqvia Holdings Inc15.50bn1.33bn28.41bn89.00k22.384.7811.581.837.347.3485.3134.330.5751--4.63176,102.304.974.036.655.1734.7234.478.647.28--3.650.70540.002.816.801.1048.360.678--
Regeneron Pharmaceuticals Inc14.09bn4.50bn59.10bn15.11k13.932.0211.834.2039.3039.30123.45271.600.39170.63472.61932,457.3012.5118.5213.8921.1386.6987.2231.9437.924.03--0.0843--8.2712.5511.6115.8415.46--
Data as of Jul 03 2025. Currency figures normalised to Regeneron Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

40.17%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20258.91m8.29%
Fidelity Management & Research Co. LLCas of 31 Mar 20257.00m6.52%
BlackRock Fund Advisorsas of 31 Mar 20255.74m5.34%
SSgA Funds Management, Inc.as of 31 Mar 20254.79m4.46%
JPMorgan Investment Management, Inc.as of 31 Mar 20253.99m3.71%
Capital Research & Management Co. (International Investors)as of 31 Mar 20253.99m3.71%
Geode Capital Management LLCas of 31 Mar 20252.47m2.30%
Dodge & Coxas of 31 Mar 20252.32m2.16%
T. Rowe Price Associates, Inc. (IM)as of 31 Mar 20252.02m1.88%
Capital Research & Management Co. (World Investors)as of 31 Mar 20251.94m1.80%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.